TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Ongoing prospective studies are further investigating the efficacy of BV + CHP in the frontline setting for PTCL with CD30 expression <10% (clinicaltrial.gov ID NCT04569032) [26].